PKTX · XBRL financial data
ProtoKinetix financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PKTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 527 | 436 | 449 | 112 | 100 | 107 |
| General and administrative | 209 | 317 | 163 | 100 | 61 | 58 |
| Total operating expenses | 7,644 | 2,329 | 1,907 | 415 | 364 | 394 |
| Income tax expense (benefit) | 0 | 0 | — | 0 | 0 | 0 |
| Net income (loss) | (7,644) | (2,329) | (1,907) | (415) | (364) | (394) |
| Earnings per share, basic USD per share | — | — | (0.01) | (0.01) | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | — | — | (0.01) | (0.01) | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | — | — | 307,392 | 333,103 | 358,558 | 386,285 |
| Weighted average shares, diluted thousands of shares | 278,599 | 291,866 | 307,392 | 333,103 | 358,558 | 386,285 |
Balance sheet
CSVFiscal years (PKTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 193 | 58 | 26 | 20 | 5 | 1 |
| Total current assets | 194 | 84 | 27 | 21 | — | — |
| Total assets | 469 | 446 | 463 | 481 | 466 | 483 |
| Accounts payable | 45 | 93 | 42 | 45 | 124 | 185 |
| Accrued liabilities | 27 | — | — | — | — | — |
| Total current liabilities | 18 | 93 | 42 | 45 | 124 | 185 |
| Total liabilities | 45 | — | — | — | — | — |
| Accumulated deficit | (43,193) | (45,541) | (47,448) | (47,864) | (48,228) | (48,622) |
| Total stockholders' equity | 424 | 353 | 421 | 436 | 342 | 298 |
| Total liabilities and equity | 469 | 446 | 463 | 481 | 466 | 483 |
| Common shares outstanding (cover page) thousands of shares | 289,127 | 299,530 | 322,880 | 346,713 | 377,580 | 411,630 |
Cash flows
CSVFiscal years (PKTX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (7,644) | (2,329) | (1,907) | (415) | (364) | (394) |
| Stock-based compensation | 6,741 | 1,413 | 1,071 | 0 | 5 | 0 |
| Net cash from operating activities | (881) | (890) | (805) | (376) | (223) | (135) |
| Net cash from investing activities | (70) | (91) | (132) | (59) | (58) | (56) |
| Proceeds from issuing common stock | 768 | 845 | 905 | 251 | 256 | 198 |
| Net cash from financing activities | 768 | 845 | 905 | 430 | 256 | 198 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| ProtoKinetix | 1.1 | not reported | 0.6* | 411.6M | — | 10-KDec 31, 2025 |
| Galera Therapeutics | 5,500 | not reported | (875) | 160.4M | 6.3 quarters | 10-QMar 31, 2026 |
| Agentix | 0 | not reported | (26) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
| Decoy Therapeutics | 8,289 | 228 | (2,652)* | 655,185 | 3.1 quarters | 10-QJun 30, 2026 |
| Nomad Power Solutions | 12,670 | not reported | (1,612)* | 16.1M | 7.9 quarters | 10-QJun 30, 2026 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| Regen BioPharma | 0.2 | 59 | (24)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 13 | not reported | (907)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Cannapharmarx | 0.6 | 276 | (127)* | 708.7M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.